EP0528764B1 — Inhaler for administration of powdery substances
Assigned to Novartis Pharma GmbH Austria · Expires 1996-06-12 · 30y expired
What this patent protects
An inhaler for administering powdered medicaments comprising a one-piece, elongate body (4) that has an elongate magazine (32) in a magazine passage extending through the elongate body. The elongate body also has an air inlet (16), a mouthpiece (20), and a capsule cutter (52). Th…
USPTO Abstract
An inhaler for administering powdered medicaments comprising a one-piece, elongate body (4) that has an elongate magazine (32) in a magazine passage extending through the elongate body. The elongate body also has an air inlet (16), a mouthpiece (20), and a capsule cutter (52). The elongate magazine has a plurality of capsule chambers (34) defined in it and spaced along its length, each capsule chamber having an air inlet (38) alignable with the air inlet to the elongate body and an air outlet alignable with the mouthpiece. The magazine is slidable step-wise along the magazine passage to align a capsule chamber with the air inlet to the elongate body, the mouthpiece and the capsule cutter. The capsule cutter, upon activation, pierces both ends of a capsule in the capsule chamber. <IMAGE>
Drugs covered by this patent
- Remodulin (TREPROSTINIL) · United Therap
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.